Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
Christoph FriedliFranca WagnerHammer Helly NoemiKamber NicoleWiest RolandLara DiemChan AndrewSalmen AnkeHoepner RobertPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
We observed LME resolution under treatment with anti-CD20 therapies. As LME might play an important role in cerebral gray matter pathology in MS, further investigations including extensions to higher field strengths, correlation with clinical phenotypes, and comparison with other immunotherapies are needed.